Clinical Performance of the New Plasma Filter PX2 in TPE Treatments

Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18+
SponsorFresenius Medical Care Deutschland GmbH

About this trial

The plasma filter is applied for a single use in extracorporeal blood purification therapy. The intended purpose is the separation of plasma from blood by filtration, in conditions, which are associated with increased concentration of plasma components where a rapid depletion slows down or stops a pathogenic process.

The investigation involves the collection of treatment data of the new Plasma Filter PX2 in combination with the multiFiltrate and multiFiltratePRO in therapeutic plasma exchange (TPE) treatments. The multiFiltrate and multiFiltratePRO are devices for extracorporeal blood purification treatments. No further control treatments will be investigated in this one arm design. The design is considered to be appropriate to reflect daily clinical practice and to contribute to empirical evidence of performance of the new Plasma Filter PX2. No specific treatment schedule is defined by the study protocol. The TPE treatment is performed with the plasma filter PX2 (investigational device) according to clinical practice established in each of the participating centers and are prescribed at the discretion of the treating physician. The participation in the study will have no influence on the treatment plan. The documentation of the treatment includes the therapy up to the tenth (10th) treatment.

Eligibility criteria

Qualifiers

Informed consent signed and dated by study patient and investigator/authorized physician

Minimum age of 18 years

Patients with an indication for a therapeutical plasma exchange

Patients to be treated with the plasma filter PX2 in combination with the multiFiltrate or multiFiltratePRO

Disqualifiers

Patients with known or suspected hypersensitivity to any of the materials of the PX2 plasma filter (Polysulfone, Polyvinylpyrrolidone, Polypropylene, Polyurethane, Silicone) and trial related products

Patients suffering from a heparin allergy

Patients with a prescription for TPE treatment with the completion of < 0.8 PV and > 2.0 PV

Any conditions which could interfere with the patient's ability to comply with the study

Trial design

Treatments tested in this trial

  • Therapeutic Plasma Exchange (TPE) with the Plasma Filter PX2

Treatment groups

46 Participants
are divided into 1 treatment group

Sponsors and collaborators